Epidemiological surveys indicate that the incidence of inflammatory bowel disease (IBD) is
increasing rapidly with the continuous growth of the economy. A large number of studies …

The human gastrointestinal tract is inhabited by the largest microbial community within the
human body consisting of trillions of microbes called gut microbiota. The normal flora is the …

Inflammatory bowel disease can be caused by the dysfunction of the intestinal mucosal
barrier and dysregulation of gut microbiota. Traditional treatments use drugs to manage …

Reactive oxygen species (ROS) play vital roles in intestinal inflammation. Therefore,
eliminating ROS in the inflammatory site by antioxidant enzymes such as catalase and …

Background Alteration of the gut microbiota may contribute to the development of
inflammatory bowel disease (IBD). Epigallocatechin-3-gallate (EGCG), a major bioactive …

Hyaluronic acid (HA) is a natural polymer, produced endogenously by the human body,
which has unique physicochemical and biological properties, exhibiting desirable …

Immunotherapy is used to regulate systemic hyperactivation or hypoactivation to treat
various diseases. Biomaterial‐based immunotherapy systems can improve therapeutic …

Immunomodulation of tumor‐associated macrophages (TAMs) into tumor‐inhibiting M1‐like
phenotype is a promising but challenging strategy. Cleverly, tumor cells overexpress CD47 …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

Overproduction of reactive oxygen species (ROS), a key characteristic of inflammatory bowel
disease (IBD), is responsible for dysregulation of signal transduction, inflammatory …